dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

History

  • A detailed medical and family history reduces the differential diagnoses
  • Review medications for possible causes of dyspepsia eg Ca antagonists, nitrates, theophyllines, bisphosphonates, steroids and nonsteroidal anti-inflammatory drugs (NSAIDs), Aspirin, Acarbose, Orlistat, potassium supplements

Physical Examination

  • Often normal except for epigastric tenderness
  • Other PE findings may help diagnose or exclude other diseases eg right upper quadrant pain with cholelithiasis, palpable abdominal mass in hepatoma, lymphadenopathy in gastric malignancy

Laboratory Tests

  • Complete blood counts and chemistries (eg LFTs) may be performed to identify alarm features or metabolic diseases causing dyspepsia or to investigate patients who have been unresponsive to treatment

Complications

  • Symptoms that suggest complicated disease must be recognized and patients referred immediately for further diagnostic testing
    • GI bleeding
    • Epigastric mass
    • Iron-deficiency anemia
    • Persistent vomiting
    • Progressive dysphagia
    • Suspicious barium meal
    • Unintentional weight loss
    • Persistent nocturnal symptoms
    • Family history of upper GI cancer
    • Lymphadenopathy
    • Jaundice
    • Painful swallowing

Non-ulcer Dyspepsia or Functional Dyspepsia

  • Patients have >1 bothersome dyspepsia symptoms (eg epigastric pain or burning, early satiety, postprandial fullness) and without evidence of structural disease, including a normal upper endoscopy, that can explain the symptoms
  • Includes subcategories that can overlap: 
    • Postprandial distress syndrome (dyspepsia symptoms caused by meals): Includes 1 or both of the following for at least 3 days/week: Bothersome postprandial fullness or early satiety 
    • Epigastric pain syndrome (dyspepsia symptoms that do not occur exclusively postprandially and can be improved by meals): Includes at least 1 of the following for at least 1 day/week: Bothersome epigastric pain and/or burning   
  • Criteria must be fulfilled for postprandial distress syndrome and/or epigastric pain syndrome and fulfilled for the  last 3 months with symptoms starting at least 6 months prior to diagnosis (Rome IV criteria)
  • No evidence is documented on routine evaluation (including upper endoscopy) of organic, systemic or metabolic disease that can explain the symptoms
  • Patients with this diagnosis should be treated similarly as those with uninvestigated dyspepsia provided they meet the following criteria:
    • No heartburn
    • No NSAID or low-dose Aspirin use
    • Normal blood tests
    • No evidence of an abnormality
  • H pylori eradication therapy is effective for patients with H pylori-positive functional dyspepsia 
    • Patients without symptoms 6-12 months following H pylori eradication therapy can be classified as H pylori-associated functional dyspepsia 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

12 Apr 2017
Patients with fibromyalgia syndrome (FMS) are at an increased risk of peptic ulcer disease (PUD), a new study shows.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.
01 Jun 2015
A mixture of the flavonoids diosmin, troxerutin, and hesperidin is safe and effective for the symptomatic management of patients with acute haemorrhoidal disease, a prospective, randomised, triple-blind, controlled trial revealed.